reports
Alcon Agrees to Acquire LENSAR, Inc.
GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR. The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline® software technology and LENSAR legacy laser system, building Alcon’s femtosecond...
Alcon to Host 2025 Capital Markets Day
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will host its 2025 Capital Markets Day on March 27, 2025, beginning at 8:00 a.m. CT. A live webcast of the event will be available at the following link: . Those wishing to participate should register and log on approximately 10 minutes before the start of the webcast. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care product...
Alcon Canada renforce son engagement envers les patients atteints d’as...
TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé aujourd’hui l’ajout de paramètres élargis à la gamme de lentilles TOTAL30MD pour l’astigmatisme, les premières et les seules lentilles cornéennes toriques à remplacement mensuel avec gradient d’eau1-3 qui procurent la même expérience de port exceptionnellement confortable5, maintenant offertes avec une puissance cylindrique de -2,75 D. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : L...
Alcon Canada Strengthens its Commitment to Astigmatic Patients with TO...
TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens,1-3 delivering the same exceptionally comfortable wearing experience,5 now in a –2.75D cylinder offering. This press release features multimedia. View the full release here: TOTAL30 for Astigmatism, the first and only monthly replacement Water Gradient toric contact lens, is now available in expanded parameters. (...
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earning...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2024. For the fourth quarter of 2024, sales were $2.5 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.57 and core diluted earnings per share2 of $0.72 in the fourth quarter of 2024. "In 2024, our unwavering focus on innovation and operational excellence delivered another set of strong results," said Dav...
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revo...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of SYSTANE® PRO Preservative-Free (PF) as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a unique triple action, preservative-free formula for the temporary relief of burning and irritation due to dryness of the eye.1 Dry eye disease is one of the most common ocular surface disorders, affecting an estimated 45.5 million people in the Uni...
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatme...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager™ DSLT, the first and only Direct Selective Laser Trabeculoplasty device (DSLT). Voyager DSLT is uniquely poised to accelerate the adoption of laser as a first-line therapy, unlocking the treatment’s availability for more patients. Designed for an exceptional patient and physician experience, Voyager DSLT is fully automated—efficiently delivering 120 laser pulses without the need for a gonio lens as with man...
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC) CEO David Endicott will present at the 2025 J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 p.m. PST. A live webcast of the conference will be available at . About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataract...
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2024. For the third quarter of 2024, sales were $2.4 billion, an increase of 6% on a reported and constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.53 and core diluted earnings per share2 of $0.81 in the third quarter of 2024. "Our third quarter results reflect our broad geographic footprint and excellent execution by our team. These elements contrib...
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7®, the only one-week replacement contact lens with the revolutionary 7-day ACTIV-FLO® System2 that provides 16 hours of outstanding comfort and precise vision, even on day 7.1 While nearly nine out of ten Eye Care Professionals (ECPs) believe daily disposable lenses are better overall for their patients, more than half of new patients are still being fit in reusable lenses due to cost considerations.3* Most optometrists agree ...
Alcon Singapore Elevates Associate Experience with Inspiring Engagemen...
SINGAPORE--(BUSINESS WIRE)-- Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that it has been named one of the ‘Best Employers in Singapore’ for the second consecutive year in addition to its recognition in 2021. This prestigious recognition underscores Alcon’s unwavering commitment to building a strong culture of excellence where all associates can bring their best to work. In this year’s survey, Alcon achieved second place in the ‘Health Care Equipment & Services’ industry category compared to third place in 2023. This accolade comes from a ...
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Pe...
FORT WORTH, Texas--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry leaders can visit Alcon at booth #4008 for hands-on demonstrations and engaging experiences. “The heart of Alcon remains a relentless pursuit of improving outcomes and helping patients see brilliantly,” said Jim Di Filippo, Vice President and General Manager of U....
Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implan...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.45 and core diluted earnings per share2 of $0.74 in the second quarter of 2024. "We are pleased with our solid second-quarter results, which were driven by robust demand for our innovative produc...
Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unit...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. These innovations are the first to be introduced from Alcon’s highly anticipated Unity portfolio. “At Alcon, we have a long legacy of involving our customers throughout the research and development process to deliver bold innovation in ophthalmology, and we would like to thank those who helped us arrive a...
Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales...
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.50 and core diluted earnings per share2 of $0.78 in the first quarter of 2024. "Our first-quarter results reflect the outstanding work done by our more than 25,000 associates across both our Surgical and Vision ...
Alcon Announces Results of 2024 Annual General Meeting
GENEVA--(BUSINESS WIRE)-- Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,068,314.80, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who all stood for re-election, namely Lynn Bleil, Raquel Bono, Arthur Cumm...
Alcon Publishes Agenda for 2024 Annual General Meeting
GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to the AGM, including explanatory information on individual agenda items, will be publishe...
Alcon Strengthens Leadership in IOL Innovation with the launch of the ...
BENGALURU, India--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India. Utilizing Alcon’s most advanced IOL material in its 20+ years of IOL innovation, Clareon delivers consistent visual outcomes and exceptional clarity that lasts.°,12-18 Clareon’s clarity is born out of a glistening-free§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs.†,*,12-14 The Clareon pla...
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5¤ “Reaching the one million milestone for Vivity, the world's leading EDOF IOL, rep...
Vivity, la LIO à profondeur focale accrue première au monde, atteint u...
TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE : ALC), le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir brillamment, annonce aujourd’hui fièrement que les lentilles intraoculaires (LIO) à profondeur focale accrue AcrySofMD IQ VivityMD et ClareonMD Vivity ont dépassé plus d’un million d’implants dans le monde. Vivity est la LIO à profondeur focale accrue la plus implantée à l’échelle mondiale.1* Alcon est le chef de file mondial dans le domaine des LIO – toutes les quatre secondes une LIO Alcon est implantée – et continue d’innover dans ce domaine pour r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.